亚洲一区二区三区看片,日韩欧美九九九久久久,精品国产日韩亚洲一区在线,久久噜噜噜久久熟女精品

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
国产亚洲精品久久yy50,亚洲精品成人网久久久久久小说,日韩av一区二区精品不卡
Rabbit Anti-Angiotensin III/AP Conjugated antibody (bs-20101R-AP)
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@www.lalhoau.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@www.lalhoau.cn
說(shuō) 明 書(shū): 100ul  
100ul/2980.00元
大包裝/詢價(jià)
產(chǎn)品編號(hào) bs-20101R-AP
英文名稱1 Rabbit Anti-Angiotensin III/AP Conjugated antibody
中文名稱 堿性磷酸酶(AP)標(biāo)記的血管緊張素III抗體
別    名 ANGT_HUMAN; Angiotensin-1; Angiotensin I; Ang I; Angiotensin-2; Angiotensin II; Ang II; Ang III; Angiotensin-3; Angiotensin III; Angiotensin3; Angiotensin 3; Angiotensin-4; Angiotensin 1-4; Angiotensin 1-5; Angiotensin 1-7; Angiotensin 1-8; Angiotensin 2-8; Angiotensin 3-8; Angiotensin 1-9; Angiotensin 1-10; Angiotensinogen; Serpin A8; Angiotensin IV; Ang IV; ANHU; Des-Asp[1]-angiotensin II; SERPINA8.  
規(guī)格價(jià)格 100ul/2980元 購(gòu)買(mǎi)        大包裝/詢價(jià)
說(shuō) 明 書(shū) 100ul  
研究領(lǐng)域 心血管  免疫學(xué)  信號(hào)轉(zhuǎn)導(dǎo)  內(nèi)分泌病  脂蛋白  新陳代謝  
抗體來(lái)源 Rabbit
克隆類(lèi)型 Polyclonal
交叉反應(yīng) Mouse, Rat,  (predicted: Human, Horse, )
產(chǎn)品應(yīng)用 WB=1:50-200 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 1/50kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide of human Angiotensin III (RVYIHPF)
亞    型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
Angiotensin III is an eptapeptide drived from cleavage of full length angiotensin (AGT). AGT is a polypeptide vasopressor hormone formed by the catalytic action of renin, which is released mainly by the kidneys in response to low blood volume or low sodium content in the body. The juxtaglomerular cells release renin when juxtaglomerular apparatus decreases in the kidneys. Renin (called angiotensinogenase) is an enzyme of the hydrolase class that catalyzes cleavage of the leucine leucine bond in angiotensinogen (a serum globulin) to generate angiotensin I in the liver. Angiotensin I acts mainly as a precursor to angiotensin II, which is a vasopressor and stimulator of aldosterone secretion by the adrenal cortex, and also functions as a neurotransmitter. Angiotensin III (heptapeptide) is a degradation product of angiotensin II, and has less vasopressor activity than the parent compound. However, Angiotensin III does stimulate aldosterone release.

Function:
Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis.
Angiotensin-2: acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the zona glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone.
Angiotensin-3: stimulates aldosterone release.
Angiotensin 1-7: is a ligand for the G-protein coupled receptor MAS1. Has vasodilator and antidiuretic effects. Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets.

Subunit:
During pregnancy, exists as a disulfide-linked 2:2 heterotetramer with the proform of PRG2 and as a complex (probably a 2:2:2 heterohexamer) with pro-PRG2 and C3dg.

Subcellular Location:
Secreted.

Tissue Specificity:
Expressed by the liver and secreted in plasma.

Post-translational modifications:
Beta-decarboxylation of Asp-34 in angiotensin-2, by mononuclear leukocytes produces alanine. The resulting peptide form, angiotensin-A, has the same affinity for the AT1 receptor as angiotensin-2, but a higher affinity for the AT2 receptor.
In response to low blood pressure, the enzyme renin/REN cleaves angiotensinogen to produce angiotensin-1. Angiotensin-1 is a substrate of ACE (angiotensin converting enzyme) that removes a dipeptide to yield the physiologically active peptide angiotensin-2. Angiotensin-1 and angiotensin-2 can be further processed to generate angiotensin-3, angiotensin-4. Angiotensin 1-9 is cleaved from angiotensin-1 by ACE2 and can be further processed by ACE to produce angiotensin 1-7, angiotensin 1-5 and angiotensin 1-4. Angiotensin 1-7 has also been proposed to be cleaved from angiotensin-2 by ACE2 or from angiotensin-1 by MME (neprilysin).
The disulfide bond is labile. Angiotensinogen is present in the circulation in a near 40:60 ratio with the oxidized disulfide-bonded form, which preferentially interacts with receptor-bound renin.

DISEASE:
Essential hypertension (EHT) [MIM:145500]: A condition in which blood pressure is consistently higher than normal with no identifiable cause. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
Renal tubular dysgenesis (RTD) [MIM:267430]: Autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). Note=The disease is caused by mutations affecting the gene represented in this entry.

Similarity:
Belongs to the serpin family.

Database links:

Entrez Gene: 183 Human

Omim: 106150 Human

SwissProt: P01019 Human

Unigene: 19383 Human



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
版權(quán)所有 2004-2026 www.www.lalhoau.cn 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書(shū)編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書(shū)編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)
田东县| 华安县| 景东| 尉犁县| 肥东县| 台中市| 潼南县| 鞍山市| 永川市| 罗甸县| 龙泉市| 万宁市| 乌鲁木齐县| 灵台县| 邛崃市| 台前县| 年辖:市辖区| 岳西县| 肥城市| 望奎县| 资源县| 岫岩| 武冈市| 奇台县| 璧山县| 新兴县| 武川县| 北辰区| 四子王旗| 资中县| 东山县| 太仓市| 全南县| 乌恰县| 浦东新区| 定州市| 泽普县| 长寿区| 平舆县| 英吉沙县| 遂溪县|